MACRO
BRENT—WTI—NAT GAS—GOLD—SILVER—PLATINUM—PALLADIUM—GOLD/SILVER—COPPER—GASOLINE—COCOA—OJ—CANOLA—S&P 500—NASDAQ—DXY—FED RATE—BTC—TASI—DFM—ADX—BRENT—WTI—NAT GAS—GOLD—SILVER—PLATINUM—PALLADIUM—GOLD/SILVER—COPPER—GASOLINE—COCOA—OJ—CANOLA—S&P 500—NASDAQ—DXY—FED RATE—BTC—TASI—DFM—ADX—

RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves

April 16, 2026·CNBC BusinessMarket Movers

Disclaimer

This news item is AI-rewritten from public sources for GCC context. For informational purposes only. Not investment advice, a solicitation, or a recommendation. Consult a licensed financial advisor before making any investment decision.

GCC CONTEXT

As the incoming U.S. administration signals openness toward peptide therapies, telehealth platforms like Hims & Hers may gain regulatory tailwinds for their rapidly growing GLP-1 drug offerings, potentially creating attractive growth opportunities for GCC investors seeking exposure to the booming weight-loss and metabolic health sector. This policy shift could also influence how regional healthcare companies and investors view digital health expansion strategies in the Gulf, where telemedicine adoption continues to accelerate. For portfolio managers tracking U.S. healthcare innovation plays, such regulatory clarity may enhance the investment case for companies well-positioned in the GLP-1 space.

Read the full article at the original source:

Read at CNBC Business →︎
←︎ Back to all news